Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
July 17, 2006
- SEMINAR
July 17, 2006
- 116 Ingredients/402 Products Added in GE Drug Listing
July 17, 2006
- Taiyo Has Most GE Drugs Listed for 11th Year in a Row
July 17, 2006
- Most Generics Listed in 2006 Available in All Specifications
July 17, 2006
- Original Makers Preparing for Competition with Generics
July 17, 2006
- TOPICS 2 articles
July 17, 2006
- Marketing Companies Must Ally to Survive: Mr Eguchi
July 17, 2006
- Japan Exchanges Opinions with Chinese Regulatory Authorities
July 17, 2006
- Ain Pharmaciez Sets Up Generic Drug Wholesaler
July 17, 2006
- REGULATORY NEWS IN BRIEF
July 17, 2006
- PhRMA Applauds US Opposition for Annual NHI Price Revision
July 17, 2006
- JPA to Survey GE Drug Use in April-May
July 17, 2006
- Biliary Tract Cancer Added as an Indication of Gemzar
July 17, 2006
- OPINION：Conquering the Stress of Change
July 17, 2006
- Alfresa HD to Focus on Low-cost Operations: Mr Watanabe
July 17, 2006
- Astellas Pharma's R&D to Focus on 3 Promising Products
July 17, 2006
- NHO Slims Its Formulary, Retains Amlodin, Eliminates Norvasc
July 17, 2006
- TeGenero Files for Bankruptcy
July 17, 2006
- Novartis Pharma Taking Steps to Protect Diovan's Sales, Share
July 17, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…